SecBot SecBot
Biotech Drug Report Generated Nov 2, 2026

SYN-006

TOVX·Theriva Biologics, Inc.
NEUTRAL
Drug Impact Rating1/10
Trial phase
Preclinical
Time to market
Uncertain; the asset is preclinical and now owned by Biossil Labs with no disclosed clinical timelines. Human trials have not yet begun.
Why 1/10
SYN-006 was sold to Biossil Labs on October 30, 2026, and is no longer part of Theriva's pipeline. There are no scheduled catalysts for this drug at TOVX; any future milestone payments depend entirely on Biossil's development timeline, which has no disclosed dates. ImpactScore defaults to the low end of the scale.
Actionable Insight NEUTRAL

SYN-006 was divested to Biossil Labs on October 30, 2026. For TOVX shareholders, the asset is no longer in the pipeline; the only remaining link is potential milestone payments from Biossil, which are uncertain, shared with a third party (PREV ABR), and depend on Biossil's development timeline. Monitor Biossil's progress only as a back-end value driver.

Price Chart

Loading chart...

Executive Summary

SYN-006 is a preclinical oral carbapenemase enzyme designed to protect the gut microbiome from carbapenem antibiotic damage. It was developed by Theriva Biologics (NYSE American: TOVX) but never advanced beyond animal proof-of-concept studies. On October 30, 2026, Theriva sold SYN-006 -- along with its related antibiotic-degrading enzyme portfolio SYN-004/ribaxamase and SYN-007 -- to OpenAI-backed Biossil Labs Inc. for $350,000 upfront plus potential milestones and royalties. The asset is no longer part of Theriva's pipeline, which now focuses on oncolytic viruses (VCN-01) for cancer. For TOVX investors, SYN-006 is a divested non-factor; any future value depends on Biossil's execution and is further diluted by revenue-sharing obligations with a third party.

How It Works

SYN-006 is an oral enzyme (carbapenemase) designed to be taken by mouth alongside intravenous carbapenem antibiotics. It breaks down any carbapenem antibiotic that spills from the bloodstream into the gut, protecting the natural gut bacteria from being killed by the antibiotic. This is intended to prevent side effects like C. difficile infection and reduce the spread of antibiotic-resistant bacteria.

Trial Status

SYN-006 achieved preclinical proof-of-concept in porcine (pig) and canine (dog) models of antibiotic-mediated gut dysbiosis. It never entered human clinical trials under Theriva and has no registered trials on ClinicalTrials.gov.

The Two-Sided Case

▲ Bull Case4
SYN-006 is a novel oral carbapenemase that showed proof-of-concept in animal models for protecting the gut microbiome from carbapenem antibiotic damage, potentially reducing C. difficile infection and antibiotic resistance.
Biossil Labs is backed by OpenAI and Founders Fund with $70M+ in disclosed funding, giving it resources to potentially advance the asset.
Antibiotic resistance is a growing global health concern; if Biossil successfully develops SYN-006, it could address an unmet need and generate milestone/royalty payments for Theriva.
Theriva's divestiture allows it to focus entirely on its oncolytic adenovirus platform (VCN-01) without the distraction of the antibiotic enzyme portfolio.
▼ Bear Case5
SYN-006 never advanced beyond preclinical animal models (pig/dog); no human clinical data existed at the time of divestiture.
Theriva sold SYN-006 for only $350,000 upfront (net ~$210,000 after the PREV ABR payment), indicating limited perceived value.
The milestone payments (up to $3M regulatory, $88M sales) are highly speculative; Theriva must share 33-50% of them with PREV ABR LLC.
Biossil, despite OpenAI backing, has no approved products and is an unproven developer; SYN-006 may never reach clinical trials under its ownership.
For Theriva shareholders, SYN-006 is a divested, zero-pipeline asset; any future value depends entirely on Biossil's execution.

Upcoming Catalysts

  • None at Theriva: SYN-006 was divested on October 30, 2026. No publicly disclosed development timeline exists under Biossil Labs.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Theriva Biologics, Inc. 8-K TOVX ·Originating report

Sources · 7

Hover a chip for the title
1 therivabio.com2 sec.gov3 fiercebiotech.com4 biospace.com5 ncbi.nlm.nih.gov6 sec.gov7 allsci.com